SCHEMBL10038840

SCHEMBL10038840

CCOC(=O)CN1C(=O)CCC1NC(=O)OC(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.40
RIN1 Q13671 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
ALDH1A1 P00352 3/20 0.38
KMT2A Q03164 3/20 0.38
MEN1 O00255 1/20 0.38
TSHR P16473 1/20 0.38
NFKB1 P19838 2/20 0.36
NFKB2 Q00653 2/20 0.36
RELA Q04206 2/20 0.36
GAA P10253 1/20 0.35
CYP1A2 P05177 2/20 0.35
CYP2C9 P11712 2/20 0.35
CYP2C19 P33261 2/20 0.35
HTT P42858 1/20 0.35
GSK3A P49840 1/20 0.35
GSK3B P49841 1/20 0.35
CTSK P43235 2/20 0.34
LMNA P02545 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL524802 0.78 MEN1 (0.46) ALDH1A1KMT2AMEN1TSHRGAA
SCHEMBL7902401 0.77 ALDH1A1 (0.40) ABL1RIN1TDP1ALDH1A1KMT2A
SCHEMBL7902399 0.77 ALDH1A1 (0.40) ABL1RIN1TDP1ALDH1A1KMT2A
SCHEMBL30952422 0.74 CTSK (0.40) ALDH1A1KMT2AMEN1TSHRNFKB1
SCHEMBL21063402 0.74 CTSK (0.44) ALDH1A1KMT2AMEN1TSHRNFKB1
SCHEMBL4760675 0.73 F2 (0.48) ALDH1A1KMT2AMEN1TSHRNFKB1
SCHEMBL11555998 0.73 ABL1 (0.50) ABL1RIN1TDP1ALDH1A1KMT2A
SCHEMBL10907327 0.73 F2 (0.38) ABL1RIN1TDP1ALDH1A1KMT2A
SCHEMBL7570993 0.73 F2 (0.38) ABL1RIN1TDP1ALDH1A1KMT2A
SCHEMBL7594567 0.73 F2 (0.36) ABL1RIN1TDP1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2598504-B1 PROCESS FOR THE PREPARATION OF DIMIRACETAM NEUROTUNE AG (CH) 2014-04-16 EP disclosed
US-8476453-B2 Process for the preparation of dimiracetam NEUROTUNE AG (CH) 2013-07-02 US disclosed
US-20130123509-A1 PROCESS FOR THE PREPARATION OF DIMIRACETAM NEUROTUNE AG (CH) 2013-05-16 US disclosed
WO-2012013640-A1 PROCESS FOR THE PREPARATION OF DIMIRACETAM NEUROTUNE AG (CH) 2012-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123509-A1 PROCESS FOR THE PREPARATION OF DIMIRACETAM ADH1A, ADH1C, OGDH ABL1 1535/4885RIN1 1584/4885TDP1 3273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.